J. Gaudreault

发表

Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies.

J. Tardif, É. Rhéaume, D. Kling, 2013, Thrombosis research.

Population Pharmacokinetics of Terfenadine

R. Lalonde, J. Gaudreault, D. Lessard, 1996, Pharmaceutical Research.

Design, Construction, and In Vitro Analyses of Multivalent Antibodies

L. Presta, M. Sliwkowski, D. Lawrence, 2003, The Journal of Immunology.

Absence of Pharmacodynamic Interaction Between Inclacumab and Heparin in Healthy Smokers

C. Schmitt, Nadejda Y Mudie, J. Gaudreault, 2015, Journal of cardiovascular pharmacology.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

David M Jablons, Eric Holmgren, Roy S Herbst, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Placebo‐Controlled Evaluation of Single, Escalating Doses of CL 284,846, a Non‐Benzodiazepine Hypnotic

D. Clody, J. Ieni, J. Gaudreault, 1994, Journal of clinical pharmacology.

A population pharmacokinetic (PK) model for erlotinib (E), a small molecule inhibitor of the epidermal growth factor receptor (EGFR)

B. Lum, A. Rakhit, S. Eppler, 2005 .

Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis

A. Ravaud, C. Szczylik, P. Pisa, 2008 .

Pharmacokinetics and Anticonvulsant Effect of a New Hypnotic, CL 284,846, in Rats

F. Varin, J. Gaudreault, G. Pollack, 1995, Pharmaceutical Research.

First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin

D. Kling, M. Abt, C. Solier, 2015, Journal of cardiovascular pharmacology.

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

D. Fei, J. Gaudreault, Jeriza Rusit, 2005, Investigative ophthalmology & visual science.

Anticonvulsant pharmacodynamics and disposition of triazolam in rats.

F. Varin, J. Gaudreault, G. Pollack, 1996, Journal of pharmaceutical sciences.

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

Joan W. Miller, E. Gragoudas, Wenjun Li, 2002, Archives of ophthalmology.

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

Rene Bruno, W. Novotny, Bert Lum, 2008, Cancer Chemotherapy and Pharmacology.

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

J. Breed, W. Novotny, E. Holmgren, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis

R. Yeung, A. Hersh, P. Brunetta, 2021, Arthritis & rheumatology.

of Multivalent Antibodies Design, Construction, and In Vitro Analyses

M. Sliwkowski, D. Lawrence, A. Ashkenazi, 2017 .

Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis

L. Gibiansky, C. Chavanne, C. Jamois, 2022, Clinical and translational science.

Complexation of VEGF with Bevacizumab Decreases VEGF Clearance in Rats

Vanessa Hsei, Geralyn G. DeGuzman, Allison Nixon, 2002, Pharmaceutical Research.

Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.

Valerie Quarmby, V. Quarmby, Jihong Yang, 2007, Experimental eye research.

PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITS

L. Rangell, L. Damico, A. Ryan, 2007, Retina.

Concomitant Administration of Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin: Nonclinical Safety and Pharmacokinetics

B. Mounho, B. Christian, C. Zuch, 2005, International journal of toxicology.

Truncated Area Under the Curve as a Measure of Relative Extent of Bioavailability: Evaluation Using Experimental Data and Monte Carlo Simulations

D. Potvin, R. Lalonde, J. Lavigne, 1998, Pharmaceutical Research.

Preclinical Pharmacology and Safety of ESBA1008, a Single-chain Antibody Fragment, Investigated as Potential Treatment for Age Related Macular Degeneration

Heather S. Floyd, J. Gaudreault, D. Escher, 2012 .

Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing.

F. Kabbinavar, D. Johnson, R. Bruno, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mixed‐effects modeling of the pharmacodynamic response to the calcimimetic agent R–568

R. Lalonde, J. Gaudreault, T. Marriott, 1999, Clinical pharmacology and therapeutics.

Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies.

J. Tardif, É. Rhéaume, D. Kling, 2013, Thrombosis research.

Clinical Pharmacokinetics of Ranibizumab (LucentisTM) in Subjects With AMD

L. Damico, John B. Lowe, J. Gaudreault, 2005 .

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

R. Herbst, J. Nemunaitis, F. Kabbinavar, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A population pharmacokinetic model for bevacizumab

W. Novotny, J. Gaudreault, J. Lu, 2004 .